What women want: Lead considerations for current and future applications of noninvasive prenatal testing in prenatal care

Birth

Volumn 41, Issue 3, 2014, Pages 276-282

  Farrell, Ruth M ^a   Agatisa, Patricia K ^a   Nutter, Benjamin ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Informed consent; Maternal decision making; Prenatal genetic testing

Indexed keywords

ADULT; ANEUPLOIDY; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; DECISION MAKING; FEMALE; FORECASTING; GENETIC SCREENING; HUMAN; INFORMED CONSENT; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; PROCEDURES; QUESTIONNAIRE; TRENDS; YOUNG ADULT;

ADULT; ANEUPLOIDY; CROSS-SECTIONAL STUDIES; DECISION MAKING; FEMALE; FORECASTING; GENETIC TESTING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84906331206     PISSN: 07307659     EISSN: 1523536X     Source Type: Journal    
DOI: 10.1111/birt.12113     Document Type: Article

References (38)

1. Driscoll DA, Gross S. Clinical practice. Prenatal screening for aneuploidy. N Engl J Med 2009;360(24):2556-2562.
2. ACOG Committee on Practice B. ACOG Practice Bulletin No. 77: Screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109(1):217-227.
3. Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med 2013;369(6):499-501.
4. Fairbrother G, Johnson S, Musci TJ, Song K. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn 2013;33(6):580-583.
5. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: Results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Obstet Gynecol 2012;207(2):137. e1-137.e8.
6. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191(1):45-67.
7. Hyett J, Perdu M, Sharland G, et al. Using nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study. BMJ 1999;318(7176):81-85.
8. Benn P, Cuckle H, Pergament E. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119(6):1270-1.
9. Devers PL, Cronister A, Ormond KE, et al. Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the Position of the National Society of Genetic Counselors. J Genet Couns 2013;22(3):291-295.
10. Hill M, Fisher J, Chitty LS, Morris S. Women's and health professionals' preferences for prenatal tests for Down syndrome: A discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests. Genet Med 2012;14(11):905-913.
11. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33(6):542-546.
12. Kooij L, Tymstra T, Berg P. The attitudeof women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA. Prenat Diagn 2009;29(2):164-168.
13. Tischler R, Hudgins L, Blumenfeld YJ, et al. Noninvasive prenatal diagnosis: Pregnant women's interest and expected uptake. Prenat Diagn 2011;31(13):1292-1299.
14. Kent A. Non-invasive prenatal diagnosis: Public and patient perceptions. Semin Fetal Neonatal Med 2008;13(2):109-112.
15. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity study. BMJ 2011;342:c7401.
16. Tabor HK, Murray JC, Gammill HS, et al. Non-invasive fetal genome sequencing: Opportunities and challenges. Am J Med Genet 2012;158A(10):2382-2384.
17. Bianchi DW, Platt LD, Goldberg JD, et al. MatErnal BLood IS Source to Accuratelydiagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119(5):890-901.
18. Liang D, Lv W, Wang H, et al. Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn 2013;33(5):409-415.
19. Susanne GO, Sissel S, Ulla W, et al. Pregnant women's responses to information about an increased risk of carrying a baby with Down syndrome. Birth 2006;33(1):64-73.
20. Lyerly AD, Mitchell LM, Armstrong EM, et al. Risks, values, and decision making surrounding pregnancy. Obstet Gynecol 2007;109:979-984.
21. Fisher J. Supporting patients after disclosure of abnormal first trimester screening results. Curr Opin Obstet Gynecol 2012;24(2):109-13.
22. Michie S, Dormandy E, Marteau TM. Informed choice: Understanding knowledge in the context of screening uptake. Patient Educ Couns 2003;50(3):247-253.
23. Michie S, Smith D, Marteau TM. Prenatal tests: How are women deciding? Prenat Diagn 1999;19(8):743-748.
24. Bernhardt BA, Geller G, Doksum T, et al. Prenatal genetic testing: content of discussions between obstetric providers and pregnant women. Obstet Gynecol 1998;91(5 Pt 1):648-655.
25. Kuppermann M, Norton ME, Gates E, et al. Computerized prenatal genetic testing decision-assisting tool: A randomized controlled trial. Obstet Gynecol 2009;113(1):53-63.
26. Marteau TM, Dormandy E. Facilitating informed choice in prenatal testing: How well are we doing? Am J Med Genet 2001;106(3):185-190.
27. Khoshnood B, De Vigan C, Blondel B, et al. Women's interpretation of an abnormal result on measurement of fetal nuchal translucency and maternal serum screening for prenatal testing of Down syndrome. Ultrasound Obstet Gynecol 2006;28(3):242-248.
28. Press N, Browner CH. Why women say yes to prenatal screening. Soc Sci Med 1997;45:979-89.
29. Rothman BK. The Tentative Pregnancy: Then and Now. Columbus, OH: Ohio State University Press, 1994, 260-294.
30. Savage MS, Mourad MJ, Wapner RJ. Evolving applications of microarray analysis in prenatal diagnosis. Curr Opin Obstet Gynecol 2011;23(2):103-108.
31. Markens S, Browner CH, Press N. 'Because of the risks': How US pregnant women account for refusing prenatal screening. Soc Sci Med 1999;49:359-369.
32. Harris RA, Washington AE, Feeny D, Kuppermann M. Decision analysis of prenatal testing for chromosomal disorders: What do the preferences of pregnant women tell us? Genet Test 2001;5(1):23-32.
33. Legare F, St-Jacques S, Gagnon S, et al. Prenatal screening for Down syndrome: A survey of willingness in women and family physicians to engage in shared decision-making. Prenat Diagn 2011;31(4):319-326.
34. Farrell RM, Nutter B, Agatisa PK. Meeting patients' education and decision-making needs for first trimester prenatal aneuploidy screening. Prenat Diagn 2011;31(13):1222-1228.
35. Cho RN, Plunkett BA, Wolf MS, et al. Health literacy and patient understanding of screening tests for aneuploidy and neural tube defects. Prenat Diagn 2007;27(5):463-467.
36. de Jong A, Dondorp WJ, Frints SG, et al. Non-invasive prenatal diagnosis for aneuploidy: Toward an integral ethical assessment. Hum Reprod 2011;26(11):2915-2917.
37. Deans Z, Newson AJ. Should non-invasiveness change informed consent procedures for prenatal diagnosis? Health Care Anal 2011;19(2):122-132.
38. van den Heuvel A, Chitty L, Dormandy E, et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Educ Couns 2010;78(1):24-28.